GNE-274

• CAT Number: I045263
• CAS Number: 2369048-69-9
• Molecular Formula: C29H31NO4
• Molecular Weight: 457.56
• Purity: ≥95%
• Synonyms: (2S)-3-(3-hydroxyphenyl)-4-methyl-2-[4-[(1-propylazetidin-3-yl)methoxy]phenyl]-2H-chromen-6-ol
• InChI: InChI=1S/C29H31NO4/c1-3-13-30-16-20(17-30)18-33-25-10-7-21(8-11-25)29-28(22-5-4-6-23(31)14-22)19(2)26-15-24(32)9-12-27(26)34-29/h4-12,14-15,20,29,31-32H,3,13,16-18H2,1-2H3/t29-/m0/s1
• InChIKey: ABSGIUXAPWSTBC-LJAQVGFWSA-N
• SMILES: CCCN1CC(C1)COC2=CC=C(C=C2)[C@H]3C(=C(C4=C(O3)C=CC(=C4)O)C)C5=CC(=CC=C5)O

GNE-274（Cat No.:I045263）is a potent, selective antagonist of the bromodomain and extraterminal (BET) family protein BRD4, which regulates transcription through recognition of acetylated lysines on histones. By blocking BRD4’s bromodomain interactions, GNE-274 suppresses expression of oncogenic and inflammatory genes, including MYC. This compound has demonstrated antiproliferative effects in cancer models, particularly in hematologic malignancies and solid tumors dependent on BET signaling. GNE-274 is valuable for studying epigenetic regulation, transcriptional control, and BET-targeted therapeutic strategies. Its potency, selectivity, and suitability for in vitro and in vivo studies make it an important epigenetic research tool.